Cupid-A
64% reduction with
DUPIXENT
VS
35% reduction with
placebo
(-10.44 [n=68] vs -6.02 [n=68] [P=0.0003])
Mean ISS7 at baseline
DUPIXENT: 16.25 (SD, 3.90); Placebo: 15.74 (SD, 4.11)
Cupid-C
48% reduction with
DUPIXENT
VS
33% reduction with
placebo
(-8.50 [n=73] vs -6.13 [n=75] [P=0.0270])
Mean ISS7 at baseline
DUPIXENT: 15.18 (SD, 3.59); Placebo: 14.96 (SD, 3.94)
Cupid-A
68% reduction with
DUPIXENT
VS
36% reduction with
placebo
(-10.54 [n=68] vs -5.85 [n=68] [P=0.0001])
Mean HSS7 at baseline
DUPIXENT: 15.85 (SD, 3.76); Placebo: 15.03 (SD, 4.81)
Cupid-C
46% reduction with
DUPIXENT
VS
31% reduction with
placebo
(-7.16 [n=73] vs -5.15 [n=75] [P=0.0450])
Mean HSS7 at baseline
DUPIXENT: 13.31 (SD, 4.43); Placebo: 12.90
(SD,
4.98)
Cupid-A
66% reduction with
DUPIXENT
VS
36% reduction with
placebo
(-20.99 [n=68] vs -11.95 [n=68] [P=0.0001])
Mean UAS7 at baseline
DUPIXENT: 32.10 (SD, 7.01); Placebo: 30.76 (SD, 8.19)
Cupid-C
48% reduction with
DUPIXENT
VS
32% reduction with
placebo
(-15.61 [n=73] vs -11.27 [n=75] [P=0.0324])
Mean UAS7 at baseline
DUPIXENT: 28.48 (SD, 7.10); Placebo: 27.86 (SD, 7.82)
Proportion Of Patients With Complete response
urticaria-free (uas7=0)1,2
≈2.5x as many patients were urticaria-free vs placebo in
CUPID-A
(32% with DUPIXENT [n=68] vs 13% with placebo [n=68] [P=0.0133])
≈1.8x as many patients were urticaria-free vs placebo in
CUPID-C
(30% with DUPIXENT [n=73] vs 17% with placebo [n=75] [P=0.0165])
Significant reduction from baseline in itch (ISS7)1,2
Cupid-A
64% reduction with
DUPIXENT
vs
35% reduction with
placebo
(-10.44 [n=68] vs -6.02 [n=68] [P=0.0003])
Mean ISS7 at baseline
DUPIXENT: 16.25 (SD, 3.90); Placebo:
15.74 (SD, 4.11)
Cupid-C
48% reduction with
DUPIXENT
vs
33% reduction with
placebo
(-8.50 [n=73] vs -6.13 [n=75] [P=0.0270])
Mean ISS7 at baseline
DUPIXENT: 15.18 (SD, 3.59); Placebo: 14.96 (SD,
3.94)
Significant reduction from baseline in hives (HSS7)1,2
Cupid-A
68% reduction with
DUPIXENT
vs
36% reduction with
placebo
(-10.54 [n=68] vs -5.85 [n=68] [P=0.0001])
Mean HSS7 at baseline
DUPIXENT: 15.85 (SD, 3.76); Placebo: 15.03 (SD,
4.81)
Cupid-C
46% reduction with
DUPIXENT
vs
31% reduction with
placebo
(-7.16 [n=73] vs -5.15 [n=75] [P=0.0450])
Mean HSS7 at baseline
DUPIXENT: 13.31 (SD, 4.43); Placebo: 12.90 (SD,
4.98)
Significant reduction from baseline in (UAS7)1,2
Cupid-A
66% reduction with
DUPIXENT
vs
36% reduction with
placebo
(-20.99 [n=68] vs -11.95 [n=68] [P=0.0001])
Mean UAS7 at baseline
DUPIXENT: 32.10 (SD, 7.01); Placebo: 30.76 (SD,
8.19)
Cupid-C
48% reduction with
DUPIXENT
vs
32% reduction with
placebo
(-15.61 [n=73] vs -11.27 [n=75] [P=0.0324])
Mean UAS7 at baseline
DUPIXENT: 28.48 (SD, 7.10); Placebo: 27.86 (SD,
7.82)
PROPORTION OF PATIENTS
WITH COMPLETE RESPONSE
URTICARIA-FREE (UAS7=0)1,2
≈2.5x as many patients were
urticaria-free vs placebo in CUPID-A
(32% with DUPIXENT [n=68] vs
13% with placebo [n=68] [P=0.0133])
≈1.8x as many patients were
urticaria-free vs placebo in CUPID-C
(30% with DUPIXENT [n=73] vs
17% with placebo [n=75] [P=0.0165])
Trial Designs: 284 adults and adolescents (12-17 years) with CSU who remained symptomatic despite H1 antihistamine treatment were randomized in CUPID-A and CUPID-C to DUPIXENT or placebo. All participants were anti-IgE treatment naive and remained on a stable H1 antihistamine dose. DUPIXENT-treated adults and adolescents ≥60 kg received 300 mg Q2W after a 600 mg loading dose, and adolescents <60 kg received 200 mg Q2W after a 400 mg loading dose.1,2
Trial Efficacy Measures: Itch severity score (ISS) and hives severity score (HSS) are patient-reported assessments rated on a scale of 0 (none), 1 (mild itch/<20 hives), 2 (moderate itch/20 to 50 hives), and 3 (intense itch/>50 hives). ISS7 is the sum of the preceding 7 days’ itch scores, for a total ISS7 range of 0 to 21. HSS7 is the sum of the preceding 7 days’ hives scores, for a total HSS7 range of 0 to 21. Urticaria activity score (UAS) is the composite of ISS and HSS. UAS7 is the sum of ISS7 and HSS7 scores, for a total UAS7 range of 0 to 42.1,2
HSS7, hives severity score over 7 days; ISS7, itch severity score over 7 days; Q2W, once every 2 weeks; UAS7, urticaria activity score over 7 days.